Frontline treatment approaches in TP53-aberrant mantle cell lymphoma
Authors:
- 27 October 2022
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (1) , 230-233
Abstract
Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma with no current standard of care. Treatment options range from surveillance to intensive chemoimmunotherapy followed by autologous stem ce...Keywords
Funding Information
- Biostatistics & Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute
- National Cancer Institute and funded in part by Moffitt’s Cancer Center (P30-CA076292)
This publication has 15 references indexed in Scilit:
- Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL NetworkBlood, 2018
- TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapyBlood, 2017
- Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphomaCancer, 2016
- Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell LymphomaNew England Journal of Medicine, 2015
- High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaBlood, 2015
- Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53Blood, 2014
- CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'AdulteBlood, 2013
- Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseBlood, 2012
- Outcome of Deferred Initial Therapy in Mantle-Cell LymphomaJournal of Clinical Oncology, 2009
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood, 2008